 HC Wainwright reiterated their buy rating on shares of Crinetics Pharmaceuticals NASDAQ:CRNX in a research report released on Wednesday, Zacks.com reports. Several other research firms have also issued reports on CRNX. BidaskClub lowered Crinetics Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, March 4th. Zacks Investment Research raised ... 